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Objective: To associate the short-term effects of the Hand-
master® orthosis on disabling symptoms of the affected 
upper extremity with long-term Handmaster® orthosis use 
after stroke.
Design: Historic cohort study.
Patients: Patients with chronic stroke.
Methods: The Modified Ashworth Scale (0–5) for wrist (pri-
mary outcome) and elbow flexor hypertonia, visual ana-
logue scale (0–10) for pain, oedema score (0–3), and passive 
range of wrist flexion and extension (pROM, degrees) were 
assessed prior to Handmaster® orthosis prescription (T0), 
after 6 weeks try-out (T1) and a subsequent 4 weeks with-
hold period (T2). Long-term use was evaluated using a ques-
tionnaire. Non-parametric analyses and predictive values 
were used for statistical analyses.
Results: Of the 110 included patients 78.2% were long-term 
Handmaster® orthosis users. Long-term users showed sig-
nificant short-term (T0–T1) improvements on all impair-
ment scores and a significant relapse of wrist and elbow 
Modified Ashworth Scale (T1–T2). Non-users showed signif-
icant short-term effects on elbow Modified Ashworth Scale 
and visual analogue scale only. Positive predictive values of 
short-term effects for long-term use varied between 75% 
and 100%, with 85% (95% confidence interval (CI) 0.72–
0.93) for wrist Modified Ashworth Scale. Negative predictive 
values were low (11–27%). 
Conclusion: Short-term Handmaster® orthosis effects were 
generally beneficial for hypertonia, pain, oedema, and 
pROM, especially in long-term users. Short-term beneficial 
effects were highly predictive for long-term use, but not for 
non-use.
Key words: therapeutic electrical stimulation, long-term use, 
hypertonia, pain, stroke, cerebrovascular accident, utilization, 
upper extremity, spastic hemiplegia.
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INTRODUCTION
Neuromuscular electrical stimulation (NMES) of the upper 
limb has received considerable attention recently as a thera-
peutic modality in post-stroke rehabilitation (1, 2). Several 
commercially available NMES devices have been introduced, 
of which the Handmaster® orthosis (HMO) (NESS, Ra’anana, 
Israel) is probably one of the most widespread. This hybrid 
orthosis with built-in electrodes has been developed specifi-
cally to stimulate the extensor and flexor muscles of the paretic 
forearm as well as the thenar muscles of the hand in patients 
with central neuro logical disorders. Its primary application has 
been focused on patients who have sustained a stroke. 
Several studies in this patient population have reported posi-
tive outcomes of NMES on muscle hypertonia, while improve-
ments have also been reported for pain, oedema, and passive 
range of motion (pROM) in patients with severe paresis or 
paralysis of the affected upper extremity (3–7). In a systematic 
review, De Kroon and colleagues (2) concluded that NMES 
may have a beneficial effect on motor control and strength of 
the affected upper limb, although mainly in patients with mild 
residual motor function. Sheffler & Chae (1) arrive at a similar 
conclusion in their review, although the effect of NMES on 
arm-hand abilities and dexterity remains ambiguous. As for 
the reduction in disabling symptoms in more severely affected 
patients, published studies are relatively scarce and are based 
on small and heterogeneous samples of stroke patients (3–7). 
Yet, in clinical practice, long-term NMES is applied particu-
larly in more severely affected patients to achieve symptom 
reduction, although little is known about which patients can 
be expected to become long-term users. 
In the Netherlands, national guidelines have been developed 
by the Dutch Working Group of Rehabilitation Physicians for 
Stroke to assess the short-term effects of NMES on various 
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disabling symptoms of the affected upper extremity in order to 
better support the clinical decision-making process for long-
term prescription of this device in chronic stroke patients (i.e. 
at least 6 months post-onset), in which no NMES had been used 
in the (post-) acute phase. The development of these guidelines 
was requested by healthcare insurers, when the HMO was 
introduced on the Dutch market as the first readily applicable 
NMES device for home-based treatment, in order to obtain 
reimbursement on a case by case basis. The guidelines indicate 
that, during a try-out period of 6 weeks, individual responses 
should be monitored with regard to hypertonia, pain, oedema 
and pROM. After a withhold period of another 4 weeks, these 
short-term effects should again be evaluated and a definitive 
decision with regard to long-term prescription is made based 
on a positive response during the try-out period and a possible 
relapse in the withhold period. No specific follow-up instruc-
tions are given. Although these guidelines have been used for 
several years in the Netherlands, a formal evaluation has not 
yet been made. The goal of this study was therefore to evalu-
ate the short-term effects of the HMO on disabling symptoms 
of the affected upper extremity in patients after severe stroke, 
and to associate these findings with the actual long-term use 
of this device in these patients. Insight into this association 
may improve the efficiency and cost-effectiveness of chronic 
NMES application for the upper extremity after stroke.
METHODS
Procedure
This historical cohort study made use of a database that emerged 
from the nationwide application of guidelines for the long-term pre-
scription of the HMO in patients with chronic stroke, developed by 
the Dutch Working Group of Rehabilitation Physicians for Stroke in 
2001. These guidelines comprise a fixed protocol for the assessment 
of muscle hypertonia, pain, oedema and pROM of the affected upper 
extremity before (T0) and immediately after a 6-week try-out period 
(T1), and subsequently after a 4-week withhold period (T2). In the 
first week of the try-out period, the size of the HMO and its electrode 
positions were individually adjusted as well as the intensity, duration 
and frequency of the electrical stimuli to obtain optimal alternating 
responses of the extensor and flexor muscles of the forearm. These 
adjustments were made by a local physical or occupational therapist, 
who had been trained specifically for this purpose. After the first week, 
the frequency and duration of the stimulation were gradually increased 
up to 2–3 times, 30–45 min per day, 7 days per week, depending on 
individual goals, tolerance, and compliance. At T1, the device was 
returned to the therapist until T2. 
The applied HMO is a hybrid wrist-hand orthosis with integrated 
surface electrodes for the extensor and flexor muscles of the forearm 
and for the thenar muscles of the hand. It is attached to a control unit 
through a cable. Individual stimulation parameters (duration, frequency 
and type of pulses) are set and stored in the control unit, but the 
patients can turn the device on and off themselves, and increase the 
intensity of stimulation to a fixed maximum, when necessary. Three 
pre- programmed exercise modes and 3 functional modes provide 
stimulation to the targeted muscles: extensor digitorum communis, 
extensor pollicis brevis, flexor digitorum superficialis, flexor pollicis 
longus and thenar muscles (in the present study, only the exercise 
modes were used). The spiral design allows for wrist stabilization and 
maintains the wrist in a functional position of 10–20° dorsiflexion. 
Due to its design, patients are able to put on and take off the device 
themselves, maintaining reliable and effective electrode placement. 
At T0, T1, and T2, each of the following impairments were evalu-
ated by the local physical or occupational therapist:
•	 Muscle	hypertonia	was evaluated with the Modified Ashworth scale 
(MAS) (8) for both the affected elbow and wrist flexor muscles. With 
the patient in a sitting position, the therapist moved the elbow or 
wrist from full flexion to extension at a high velocity and observed 
the resistance to passive movement, which was classified from 0 
(no resistance) to 5 (no movement possible). Despite debate in the 
literature, the MAS is a reliable tool for assessment of post-stroke 
hypertonia when raters follow strict protocols and are well instructed 
(9). Yet, the MAS was not regarded sufficiently reliable to assess 
finger hypertonia
•	 Pain	 in	 the	 forearm	and/or	hand	was evaluated with an 11-point 
(vertical) visual analogue scale (VAS). Although a horizontal VAS is 
more common in general pain assessment (10), the vertical alterna-
tive is more appropriate for patients after stroke to prevent bias due 
to visuospatial hemi-neglect (e.g. 11). A score of 0 indicated “no 
pain” and a score of 10 indicated “intractable pain”
•	 Oedema	of	the	hand	was scored by clinical judgement on a 4-point 
scale (0: absent, 1: minimal, 2: moderate, 3: severe). Because there 
are currently no validated clinical oedema scores available, this 
ordinal scale, which is simple and straightforward, was used. 
•	 pROM	of	the	wrist	was	assessed	in 2 directions by slowly moving 
the affected hand from maximal flexion to maximal extension using 
goniometry. pROM in both directions was assessed with an accuracy 
of 5°. 
Participants
Each patient who had been prescribed the HMO between 1 July 2001 
and 1 January 2003 according to the above-mentioned guidelines in 31 
Dutch rehabilitation institutes was eligible for inclusion in the cohort. 
In early 2005, all these institutes were asked for their co-operation 
in this study. In the case of a positive answer, the patients who had 
received their HMO through this particular institute were approached 
by their treating physician and invited to participate. This procedure 
was approved by the local medical ethics committee and the patients 
who agreed to participate gave their written informed consent. For 
each patient, social demographics and the impairment scores at T0, 
T1, and T2 were collected. In addition, all patients were sent a ques-
tionnaire evaluating the actual use of the HMO (see Appendix 1), 
documenting frequency and duration of use or reasons for non-use. All 
questionnaires were filled in anonymously and returned in a stamped 
addressed envelope. Because it appeared that nearly all patients had 
baseline hypertonia of wrist flexor muscles, it was decided that the 
wrist flexor MAS was used as the primary outcome with regard to the 
short-term effects and the main determinant for predicting long-term 
use. As a consequence, patients with a MAS of 0 were excluded from 
the cohort in second instance. The data obtained with the questionnaire 
were used to categorize patients into long-term “users” or “non-us-
ers”. Users were defined as subjects who used the HMO on a daily 
basis for at least 15 min at the time of evaluation, whereas others were 
classified as non-users.
Statistical analysis
Non-parametric analyses were applied to evaluate all impairment 
scores because of their ordinal nature (hypertonia, pain, oedema) 
or non-normal distribution (pROM). First, the short-term effects of 
the HMO were evaluated using Friedman tests including data from 
all included subjects at T0, T1, and T2. Post-hoc Wilcoxon tests 
were applied to explore whether any significant changes in primary 
(hypertonia) and secondary (oedema, pain, and pROM) outcome 
measures occurred during the try-out and/or withhold periods. The 
same procedure was then followed with a split database for long-term 
users and non-users. 
Secondly, it was investigated whether short-term clinical effects, 
i.e. improvements in hypertonia, pain, oedema, and pROM, were 
associated with long-term use by calculating positive and negative 
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predictive values, including corresponding confidence intervals. To 
this end, a clinical relevant effect was defined as a reduction of at least 
1 point for the MAS, the VAS pain score, and the oedema score, and 
an improvement of at least 15 degrees for the pROM. All statistics 
were computed with SPSS 11.5 and alpha was set at 0.05 for statisti-
cal significance.
RESULTS
Patient characteristics and long-term use
The patient inclusion and categorization process is shown in 
Fig. 1. 
Of the 31 rehabilitation institutes, 17 were willing to 
participate in this study. In these 17 institutes, 148 patients 
had been prescribed the HMO during the assigned 18 month 
period, of which 127 (86%) agreed to participate and returned 
the informed consent. Seventeen patients appeared to have no 
wrist flexor hypertonia, so that 110 patients could eventually be 
included. These patients were on average 6.5 years (standard 
deviation (SD) 4.5, range 2.8–25.0) after stroke and 2.7 years 
(SD 0.6, range 1.2–4.0) post HMO prescription (see Table I 
for patient demograhics). Eighty-six patients (78.2 %) were 
defined as users. The HMO was used once a day by 37 patients 
(41.2%), twice a day by 42 patients (49.4%), and 3 times a day 
by 6 patients (7.1%). The mean duration of use was 39 min 
(SD 10, range 15–60 min). All 24 non-users (21.8%) had com-
pletely stopped using the HMO. The mean duration of HMO 
treatment in the users group was 2.7 years (SD 0.6), whereas 
the non-users had stopped HMO treatment on average 0.8 years 
(SD 0.7) after prescription. Reasons for non-use as reported by 
these patients (available for 18 of the 24 patients) were insuf-
ficient benefit (44%), side-effects (17%), epilepsy (11%), no 
reimbursement (11%), surgery of the arm (11%), and lack of 
time (6%). Users and non-users were comparable with regard 
to gender, age, hemisphere of stroke, time post-onset, as well 
as MAS, VAS pain, oedema, and pROM at T0. 
Short-term effects
For all patients together, the MAS for wrist flexors (χ2 = 43.8, 
p < 0.01), the MAS for elbow flexors (χ2 = 39.7, p < 0.01), the 
VAS pain score (χ2 = 22.6, p < 0.01), the oedema score (χ2 = 13.7, 
p < 0.01), and the passive range of wrist flexion (χ2 = 25.3, 
p < 0.01) and extension (χ2 = 18.9, p < 0.01) significantly changed 
from T0 to T2. Post-hoc analysis revealed that for both the pri-
mary and secondary outcomes an improvement was observed 
between T0 and T1, but not between T1 and T2 (see Table II).
When differentiating between users and non-users, signifi-
cant short-term effects were more present in users compared 
with non-users. The MAS for wrist flexors (χ2 = 42.1, p < 0.01), 
the MAS for elbow flexors (χ2 = 32.6, p < 0.01), the VAS 
pain score (χ2 = 15.8, p < 0.01), the oedema score (χ2 = 16.1, 
p < 0.01), and the passive range of wrist flexion (χ2 = 23.3, 
p < 0.01) and extension (χ2 = 22.5, p < 0.01) all improved in the 
user group between T0 and T2. Post-hoc analysis indicated that 
for the users, the MAS scores for the wrist and elbow flexors 
were reduced between T0 and T1 with a significant relapse 
between T1 and T2. All other impairment scores showed a 
significant change only between T0 and T1. As for the non-
users, only the MAS for the elbow flexors (χ2 = 9.7, p < 0.01) 
and the VAS pain score (χ2 = 7.8, p = 0.02) improved. Post-hoc 
analysis showed that these changes occurred between T0 and 
T1 (see Table II).
Associations between long-term use and short-term effects
The positive predictive value of a short-term effect (between 
T0 and T1) of at least 1 point on the wrist flexor MAS with 
regard to long-term use was 85% (95% confidence interval 
(CI) 0.72–0.93). 
As for the secondary outcomes, a decrease in oedema 
score and VAS pain score of at least 1 point showed positive 
predictive values of 100% (95% CI 0.40–1.0) and 80% (95% 
CI 0.62–0.91), respectively, and an increase in passive wrist 
extension and flexion of at least 15° showed positive predic-
tive values of 86% (95% CI 0.72–0.94) and 75% (0.43–0.93), 
respectively. Negative predictive values, based on the absence 
of symptom improvement between T0 and T1, were generally 
low (between 11% and 27%).
DISCUSSION
This study evaluated the short-term effects of the HMO on 
the disabling symptoms of the affected upper extremity in 
patients with chronic stroke and associated these effects with 
long-term use of the HMO in an historic cohort of 110 subjects 
Fig. 1. Flow chart of patient inclusion and categorization process. HMO: 
Handmaster® orthosis.
Table I. Patient characteristics before the start of the study (n = 110)
Entire group Users Non-users
Gender, men/women, % 51/49 51/49 50/50
Age, years, mean (SD) 57.7 (11.8) 59.5 (11.7) 56.3 (12.1)
Location stroke, left/right 
hemisphere, % 57/43 59/41 50/50
SD: standard deviation.
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with initial wrist flexor hypertonia. In all patients, HMO pre-
scription was based on the short-term effects observed during 
a 6-week try-out period and a subsequent 4-week withhold 
period. In those patients (78%) who continued using the device 
in the long term, the expected pattern of a decrease in muscle 
hypertonia during the try-out phase and a relapse of hypertonia 
during the withhold phase was found for both the wrist and 
elbow flexors. In the non-users (22%), only a reduction in 
elbow flexor hypertonia was found during the try-out phase. 
As for the secondary outcomes, the long-term users showed an 
improvement in upper extremity pain, hand oedema and wrist 
passive range of motion, whereas the non-users only showed 
a reduction of pain. Apparently, the applied protocol was able 
to predict long-term use based on a short-term reduction in 
the various symptoms, with positive predictive values varying 
between 75% and 100%, but it could not predict non-use based 
on absence of symptom reduction. The criterion for long-term 
HMO use was consciously set at 15 min per day, since experi-
ence has learned that many patients tend to seek the shortest 
duration of stimulation that is still effective to control their 
symptoms. Yet, when the lower limit would have been set at, for 
example, 30 min per day, 80 (72.7%) of the included patients 
would still have been classified as long-term users. 
The results of the present study support the literature in-
dicating the potentially beneficial effect of NMES on both 
muscle hypertonia, pain, oedema, and pROM in severely 
affected stroke patients (3–7). The added value of the current 
study is the inclusion of a large number of patients, the use 
of a predefined prescription protocol, and the observed strong 
association of short-term beneficial effects with a high percent-
age of long-term use. The association between long-term use 
and short-term effects suggests that patients benefited from 
the HMO in the long-term as well. The observed 78% long-
term use has not been reported before for any NMES device. 
Besides to a standardized selection of patients with measurable 
short-term effects, this result can probably be attributed to the 
unique design of the HMO that allows independent putting on 
and taking off the device and reproducible electrode placement 
even by severe stroke patients. No patient was specifically 
followed up to promote long-term use. 
How NMES contributes to symptom reduction after severe 
stroke is not yet fully understood. On a peripheral and spinal 
level, reciprocal and recurrent inhibition may reduce involun-
tary stimulation of spastic muscles (12, 13). Indirectly, pain and 
pROM may be improved when muscles become more relaxed, 
whereas oedema may be reduced by deep venous compression 
due to the repetitive muscle contractions induced by NMES. 
On a supraspinal level, NMES may induce neuroplasticity and 
modulate pain perception as well. Indeed, changes in (sen-
sory) cortical activation as measured by functional magnetic 
resonance imaging (fMRI) have been shown due to NMES 
application to the extensors muscles of the hemiparetic fore-
arm in patients with stroke (14). Such results suggest that the 
beneficial effects of NMES may be even more pronounced 
when applied in the subacute rather than the chronic phase 
of stroke (5).
According to clinical expectation, short-term effects were 
strongly associated with long-term HMO use. However, 
somewhat counter-intuitively, many patients without short-
term beneficial effects turned out to be long-term users as 
well. Several explanations can be given for this result. First, 
the applied outcome measures may not have been sufficiently 
sensitive to detect subclinical improvements (of the assessed 
or of a different kind) that may still be relevant for the sub-
jective evaluation by some patients. These patients (and their 
therapists) probably decided to nevertheless continue HMO 
use and await stronger effects. In the same line of reasoning, 
measurable beneficial effects might have occurred over a longer 
period than 6 weeks of stimulation. Secondly, the low negative 
predictive values for all outcome measures are probably con-
founded by the fact that most patients and therapists valued the 
improvement (and possible relapse) on one particular symptom 
important enough to continue HMO use as long as its use did 
not worsen other symptoms. Thus, lack of improvement on 
one particular symptom will not predict non-use, as long as 
improvement on another symptom is strongly associated with 
long-term use. 
Limitations
The outcome measures applied in this study may be criticized 
for their clinimetric properties. In particular the sensitivity and 
validity of the MAS and the oedema scale may be questioned. 
As for the MAS, it is well known that it cannot discriminate 
between hypertonia induced by neural activation (“spasticity”) 
and increased resistance to passive movement due to muscle 
stiffness and contracture. Hence, it might have been preferable 
Table II. Mean scores (SD) of the impairments
 
Entire group Users Non-users
T0 T1 T2 T0 T1 T2 T0 T1 T2
MAS wrist, 0–5 2.4 (1.1) 1.8 (1.1)** 2.0 (1.2)* 2.4 (1.1) 1.8 (1.1)** 2.0 (1.2)* 2.0 (1.0) 1.8 (1.1) 1.9 (1.1)
MAS elbow, 0–5 2.3 (1.1) 1.7 (1.0)** 1.8 (1.1) 2.2 (1.1) 1.6 (1.0)** 1.9 (1.1)* 2.5 (1.1) 1.9 (1.0)* 1.8 (1.1)
Oedema, 0–3 0.4 (0.7) 0.3 (0.5)** 0.3 (0.5) 0.5 (0.7) 0.3 (0.5)** 0.3 (0.5) 0.3 (0.5) 0.3 (0.5) 0.4 (0.5)
VAS, 0–10 1.8 (2.5) 0.9 (1.7)** 1.5 (2.4)* 1.8 (2.5) 1.0 (1.7)** 1.4 (2.4) 1.9 (2.6) 0.8 (1.7)* 1.6 (2.6)
Wrist flexion, ° 80.6 (16.8) 85.8 (14.2)** 83.2 (12.7) 79.8 (17.5) 85.1 (15.2)** 81.8 (13.1) 83.5 (14.2) 88.2 (9.9) 87.1 (10.8)
Wrist extension, ° 62.8 (22.1) 69.7 (20.0)** 67.9 (21.6) 61.5 (20.4) 69.9 (17.1)** 69.4 (17.9) 67.3 (26.9) 69.1 (28.4) 63.4 (30.3)
*Compared with T0, p < 0.01, **Compared with T0, p < 0.001. 
T0: before study; T1: immediately after a 6-week try-out period; T2: subsequently after a 4-week withhold period; MAS: Modified Ashworth 
scale; VAS: visual analogue scale; SD: standard deviation.
J Rehabil Med 41
161Upper limb electrical stimulation in patients after chronic stroke
when a velocity-dependent measure of hypertonia would have 
been used, since NMES may have an effect on spasticity rather 
than on stiffness and contracture. Still, the MAS is widely 
applied in clinical practice and its clinimetric properties for 
the upper extremity, the elbow in particular, have been shown 
to be quite satisfactory as long as assessors adhere to a strict 
protocol and are well instructed (9). With regard to oedema, 
there is currently no well-accepted and validated alternative. 
The retrospective design of this study may have affected the 
information (by recollection bias) about when non-users had 
stopped using the HMO. A prospective cohort study would be 
more appropriate to predict and monitor actual use, but would 
take many more years to conduct. In addition, the data obtained 
with the questionnaires might have been biased with regard to 
both frequency and duration of HMO use due to social desir-
ability. However, since all participants were informed that 
their responses would be handled anonymously, this is not 
very likely. The percentages of long-term users and non-users 
might have been different in the patients who were approached, 
but who were not willing to participate. For instance, these 
patients might be largely non-users who were dissatisfied or 
disappointed by the effects of the HMO. Because this study 
had only 14% “non-responders”, the effect of this possibility is 
probably limited. Lastly, this study may have included the most 
motivated patients as it was conducted during the introduction 
period of the HMO in the Netherlands. This notion may also 
explain the rather low prescription rate. Hence, although this 
was a nationwide study, the results cannot be readily general-
ized to other populations. 
In conclusion, significant short-term effects of the HMO 
are present in chronic stroke patients with regard to various 
disabling symptoms of their affected upper extremity. When 
based on an initial reduction of hypertonia, approximately 78% 
of the patients will continue using the HMO for more than 
2 years. Although short-term beneficial effects are strongly 
associated with long-term use, many patients without such 
short-term effects may become long-term users as well, which 
suggests the possibility of subclinical beneficial effects that 
remain undetected during a 6-week try-out period. Although 
the results were obtained using a well thought-out national 
guideline, extended use of this precise guideline is not recom-
mended. Instead, the guideline should be improved by using 
more sensitive outcome measures, including some at the level 
of activities and participation, for example by using the goal 
attainment scale. 
ACKNOWLEDGEMENTS
This study was performed on request of the national Health Care Insur-
ance Board (College Voor Zorgverzekeringen (CVZ)), an independent 
advisory board for health policymakers and insurance companies in the 
Netherlands. 
We thank the participating members of the Dutch Working Group of 
Rehabilitation Physicians for Stroke (WCN) of the Dutch Society for 
Physical Medicine and Rehabilitation (VRA).
REFERENCES 
1. Sheffler LR, Chae J. Neuromuscular electrical stimulation in 
neurorehabilitation. Muscle Nerve 2007; 35: 562–590.
2. de Kroon JR, van der Lee JH, IJzerman MJ, Lankhorst GJ. 
Therapeutic electrical stimulation to improve motor control and 
functional abilities of the upper extremity after stroke: a systematic 
review. Clin Rehabil 2002; 16: 350–360.
3. Weingarden HP, Zeilig G, Heruti R, Shemesh Y, Ohry A, Dar A, 
et al. Hybrid functional electrical stimulation orthosis system for 
the upper limb: effects on spasticity in chronic stable hemiplegia. 
Am J Phys Med Rehabil 1998; 77: 276–281.
4. Hendricks HT, IJzerman MJ, de Kroon JR, in ‘t Groen FA, 
Zilvold G. Functional electrical stimulation by means of the “Ness 
Handmaster Orthosis” in chronic stroke patients: an exploratory 
study. Clin Rehabil 2001; 15: 217–220.
5. Ring H, Rosenthal N. Controlled study of neuroprosthetic func-
tional electrical stimulation in sub-acute post-stroke rehabilitation. 
J Rehabil Med 2005; 37: 32–36.
6. Santos M, Zahner LH, McKiernan BJ, Mahnken JD, Quaney 
B. Neuromuscular electrical stimulation improves severe hand 
dysfunction for individuals with chronic stroke: a pilot study. J 
Neurol Phys Ther 2006; 30: 175–183.
7. Sullivan JE, Hedman LD. Effects of home-based sensory and mo-
tor amplitude electrical stimulation on arm dysfunction in chronic 
stroke. Clin Rehabil 2007; 21: 142–150.
8. Bohannon RW, Smith MB. Interrater reliability of a modified Ash-
worth scale of muscle spasticity. Phys Ther 1987; 67: 206–207.
9. Gregson JM, Leathley M, Moore AP, Sharma AK, Smith TL, 
Watkins CL. Reliability of the Tone Assessment Scale and the 
modified Ashworth scale as clinical tools for assessing poststroke 
spasticity. Arch Phys Med Rehabil 1999; 80: 1013–1016.
10. Gift A. Visual analogue scales: measurement of subjective phe-
nomena. Nursing Res 1984; 38: 286–288.
11. Pomeroy VM, Frames C, Faragher EB, Hesketh A, Hill E, Watson 
P, et al. Reliability of a measure of post-stroke shoulder pain in 
patients with and without aphasia and/or unilateral spatial neglect. 
Clin Rehabil 2000; 14: 584–591.
12. Eisen A. Electromyography in disorders of muscle tone. Can J 
Neurol Sci 1987; 14: 501–505.
13. Sehgal N, McGuire JR. Beyond Ashworth. Electrophysiologic 
quantification of spasticity. Phys Med Rehabil Clin N Am 1998; 
9: 949–979.
14. Kimberley TJ, Lewis SM, Auerbach EJ, Dorsey LL, Lojovich JM, 
Carey JR. Electrical stimulation driving functional improvements 
and cortical changes in subjects with stroke. Exp Brain Res 2004; 
154: 450–460.
APPENDIX I. Patient questionnaire.
Do you still use the Handmaster?
• Yes, I still use the Handmaster.
How often a day (on average) are you using the Handmaster?
…. a day.
How long (on average) are you using the Handmaster each time?
…. minutes.
• No, I do not use the Handmaster any longer.
Why did you stop using the Handmaster?
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